ATE395344T1 - Kalzilytische verbindungen - Google Patents

Kalzilytische verbindungen

Info

Publication number
ATE395344T1
ATE395344T1 AT04784821T AT04784821T ATE395344T1 AT E395344 T1 ATE395344 T1 AT E395344T1 AT 04784821 T AT04784821 T AT 04784821T AT 04784821 T AT04784821 T AT 04784821T AT E395344 T1 ATE395344 T1 AT E395344T1
Authority
AT
Austria
Prior art keywords
calcilytic compounds
calcilytic
compounds
Prior art date
Application number
AT04784821T
Other languages
English (en)
Inventor
Robert Marquis
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE395344T1 publication Critical patent/ATE395344T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D321/00Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04784821T 2003-09-24 2004-09-23 Kalzilytische verbindungen ATE395344T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50600103P 2003-09-24 2003-09-24

Publications (1)

Publication Number Publication Date
ATE395344T1 true ATE395344T1 (de) 2008-05-15

Family

ID=34393099

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04784821T ATE395344T1 (de) 2003-09-24 2004-09-23 Kalzilytische verbindungen

Country Status (9)

Country Link
US (1) US20070203226A1 (de)
EP (1) EP1664013B1 (de)
JP (1) JP2007506751A (de)
AR (1) AR045799A1 (de)
AT (1) ATE395344T1 (de)
DE (1) DE602004013802D1 (de)
ES (1) ES2303099T3 (de)
TW (1) TW200524892A (de)
WO (1) WO2005030749A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
US20090304821A1 (en) * 2006-03-08 2009-12-10 Takeda Pharmaceutical Company Limited Pharmaceutical Combination
EP2079739A2 (de) 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-onderivate als kalziumrezeptorantagonisten
PL2292592T3 (pl) * 2008-06-05 2013-01-31 Asahi Kasei Pharma Corp Związki sulfonamidowe i ich zastosowanie
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239342A (en) * 1965-02-15 1966-03-08 Commercial Solvents Corp Estrogenic compounds and animal growth promoters
DE69824855T2 (de) * 1997-07-25 2005-08-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Macrozyklische laktone, zusammensetzungen und verfahren zur verwendung
ID28460A (id) * 1998-07-08 2001-05-24 Lipogenics Inc Komposisi dan metoda untuk perlakuan dan pencegahan penyakit tulang dengan menggunakan tocotrienol
JP2003113183A (ja) * 2001-10-05 2003-04-18 Kyowa Hakko Kogyo Co Ltd リウマチ治療剤

Also Published As

Publication number Publication date
DE602004013802D1 (de) 2008-06-26
US20070203226A1 (en) 2007-08-30
EP1664013A4 (de) 2007-03-14
JP2007506751A (ja) 2007-03-22
AR045799A1 (es) 2005-11-16
EP1664013A1 (de) 2006-06-07
EP1664013B1 (de) 2008-05-14
ES2303099T3 (es) 2008-08-01
TW200524892A (en) 2005-08-01
WO2005030749A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
CY2023008I1 (el) Χημικες ενωσεις
ATE549329T1 (de) Chinazoline verbindungen
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
IS8108A (is) Ný efnasambönd
SE0301569D0 (sv) Novel compounds
IS8228A (is) Ný asetídínefnasambönd
IS8513A (is) Lífræn efnasambönd
NO20055688D0 (no) Organiske forbindelser
IS8089A (is) Efnasambönd
IS8292A (is) Ný efnasambönd
DK1651034T4 (da) Organiske forbindelser
ATE405574T1 (de) Aryl-annellierte azapolyzyklische verbindungen
DK1569892T3 (da) Kalcilytiske forbindelser
ATE395344T1 (de) Kalzilytische verbindungen
NO20034952D0 (no) Farmasöytiske forbindelser
NO20031736D0 (no) Forbindelser
SE0303452D0 (sv) New compounds
NO20055170D0 (no) Organiske forbindelser
NO20035294D0 (no) Forbindelser
NO20030117D0 (no) Forbindelser
NO20033173D0 (no) Forbindelser
SE0300388D0 (sv) Novel compounds
SE0300118D0 (sv) Novel Compounds
SE0302667D0 (sv) Novel Compounds
SE0303493D0 (sv) New compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties